ATE354374T1 - Zusammensetzungen und methoden zur katalysierten hydrolyse von hiv gp120 - Google Patents

Zusammensetzungen und methoden zur katalysierten hydrolyse von hiv gp120

Info

Publication number
ATE354374T1
ATE354374T1 AT96926751T AT96926751T ATE354374T1 AT E354374 T1 ATE354374 T1 AT E354374T1 AT 96926751 T AT96926751 T AT 96926751T AT 96926751 T AT96926751 T AT 96926751T AT E354374 T1 ATE354374 T1 AT E354374T1
Authority
AT
Austria
Prior art keywords
pct
hiv
methods
compositions
catalyzed hydrolysis
Prior art date
Application number
AT96926751T
Other languages
English (en)
Inventor
Sudhir Paul
Ravishankar Kalaga
Original Assignee
Univ Nebraska
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Nebraska filed Critical Univ Nebraska
Application granted granted Critical
Publication of ATE354374T1 publication Critical patent/ATE354374T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0002—Antibodies with enzymatic activity, e.g. abzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1145—Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
AT96926751T 1995-07-21 1996-07-19 Zusammensetzungen und methoden zur katalysierten hydrolyse von hiv gp120 ATE354374T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US132195P 1995-07-21 1995-07-21

Publications (1)

Publication Number Publication Date
ATE354374T1 true ATE354374T1 (de) 2007-03-15

Family

ID=21695441

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96926751T ATE354374T1 (de) 1995-07-21 1996-07-19 Zusammensetzungen und methoden zur katalysierten hydrolyse von hiv gp120

Country Status (8)

Country Link
US (1) US6156541A (de)
EP (1) EP0871485B1 (de)
JP (2) JPH11510047A (de)
CN (1) CN1165344C (de)
AT (1) ATE354374T1 (de)
CA (1) CA2223914A1 (de)
ES (1) ES2283005T3 (de)
WO (1) WO1997003696A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1293511B1 (it) * 1997-07-30 1999-03-01 Gentili Ist Spa Anticorpi monoclonali catalitici ad attivita' proteasica per la lisi selettiva della componente proteica di placche e aggregati correlati
WO1999033968A1 (fr) * 1997-12-26 1999-07-08 Taizo Uda Procede de production d'anticorps catalytique et son procede d'utilisation
RU2221873C2 (ru) 2001-04-24 2004-01-20 Закрытое акционерное общество "АСГЛ-Фармацевтические Инновации" Способ получения каталитических антител (варианты), антигены для иммунизации и нуклеотидная последовательность
US7560529B2 (en) 2001-04-24 2009-07-14 FDS Pharma Method for producing catalytic antibodies (variants), antigens for immunization and nucleotide sequence
WO2004087059A2 (en) 2003-03-26 2004-10-14 The University Of Texas Covalent attachment of ligands to nucleophilic proteins guided by non-covalent binding
EP1615946B1 (de) * 2003-03-26 2020-05-06 Sudhir Paul Proteolytische und kovalente antikörper
CA2520382C (en) * 2003-03-27 2014-01-28 Sudhir Paul Lupus antibodies for passive immunotherapy of hiv/aids
WO2007023815A1 (ja) * 2005-08-23 2007-03-01 Yamasa Corporation 心疾患及びウイルス性疾患治療薬
US8202523B2 (en) * 2005-09-22 2012-06-19 ProSci, Inc. Glycosylated polypeptides produced in yeast mutants and methods of use thereof
CA2637600A1 (en) 2006-01-17 2007-07-26 Health Research, Inc. Heteroduplex tracking assay
WO2008035894A1 (en) 2006-09-19 2008-03-27 Sungkyunkwan University Foundation For Corporate Collaboration Antiviral agent against animal viruses
EP2190875B1 (de) * 2007-04-23 2019-07-10 Sudhir Paul Katalytische Antikörper gegen HIV gp120
US9969797B2 (en) 2008-04-23 2018-05-15 Covalent Bioscience Incorporated Immunoglobulins directed to bacterial, viral and endogenous polypeptides

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5229272A (en) * 1989-04-25 1993-07-20 Igen, Inc. Catalytic antibody components
ZA893284B (en) * 1988-05-04 1990-03-28 Igen Inc Peptide analogs and their use as haptens to elicit catalytic antibodies
US5318897A (en) * 1989-04-25 1994-06-07 Igen, Inc. Monoclonal antibody and antibody components elicited to a polypeptide antigen ground state
US5672683A (en) * 1989-09-07 1997-09-30 Alkermes, Inc. Transferrin neuropharmaceutical agent fusion protein
EP1690935A3 (de) * 1990-01-12 2008-07-30 Abgenix, Inc. Bildung von xenogenen Antikörpern
ES2246502T3 (es) * 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
ZA931263B (en) * 1992-02-24 1993-11-02 Igen Inc Reaction-based selection for expression of and concentration of catalytic moieties
ES2301158T3 (es) * 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
AU6819494A (en) * 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies

Also Published As

Publication number Publication date
CN1197394A (zh) 1998-10-28
ES2283005T3 (es) 2007-10-16
CA2223914A1 (en) 1997-02-06
JP2007332151A (ja) 2007-12-27
US6156541A (en) 2000-12-05
EP0871485B1 (de) 2007-02-21
JP4185151B2 (ja) 2008-11-26
WO1997003696A1 (en) 1997-02-06
CN1165344C (zh) 2004-09-08
JPH11510047A (ja) 1999-09-07
EP0871485A1 (de) 1998-10-21
EP0871485A4 (de) 2000-05-03

Similar Documents

Publication Publication Date Title
DE59409832D1 (de) Pflaster zur behandlung von nagelmykosen
ATE125157T1 (de) Methoden und zusammensetzungen zur impfung gegen hiv.
MX9706913A (es) Compuestos de bis-aminacido-hidroxietilamina-sulfonamida inhibidoresde proteasan retroviral, composiciones que los contienen y ek uso de los mismos.
EP0871485A4 (de) Zusammensetzungen und methoden zur katalysierten hydrolyse von hiv gp120
NL300787I2 (de)
DE69830751D1 (de) Polyaromatische Verbindungen zur Behandlung von Herpes-Infektionen
PT815124E (pt) Inibidores protease retroviral sulfonamida hidroxietilamino aminoacido heterociclocarbonilo
BR9607638A (pt) Inibidores de protease retrovirais de hidroxietilamino sulfonamida de aminoácido
ATE201014T1 (de) Sulfonylalkanoylamino-hydroxyethylamino- sulfonamide als inhibitoren des retroviralen protease
ID21682A (id) Turunan-turunan pirolo [3,4-d] pirimidinon dan penggunaannya sebagai obat-obatan
ATE235506T1 (de) Behandlung einer proteinlösung mit a1/fe und anschliesende membrankonzentration
AU7635396A (en) Treatment and diagnosis of infections due to helicobacter pylori
ES2132383T3 (es) Inhibidores de proteasa hiv.
ATE204851T1 (de) Verfahren zur herstellung von retrovial protease hemmenden zwischenprodukten
ES2170251T3 (es) (s)-hidroxinitriloliasa de hevea brasiliensis.
DE60213874D1 (de) Verfahren zur herstellung von protease hemmenden zwischenprodukten
DK0651791T3 (da) Fremgangsmåde til oprensning af vandig enzymopløsning
KR950700988A (ko) 미생물, 이들의 제조방법 및 이들의 사용(Micro-organisms, preparation method therefor and uses thereof)
AU4312093A (en) Use of a hymenoptera venom for the manufacture of a medicament for treating dna virus infections
DE69922364D1 (de) Verfahren zur immunisierung und behandlung von h. pylori infektion
DE69626276D1 (de) Tetronsäurederivate zur behandlung von hiv- und anderen retroviruserkrankungen
DE59611353D1 (de) Transketolase-verwandtes protein
DE69636924D1 (de) Zusammensetzungen und methoden zur katalysierten hydrolyse von hiv gp120
IL129727A0 (en) 1-(3-Aminoindazol-5-YL)-3-phenylmethyl-cyclic ureas useful as HIV protease inhibitors
ATE175668T1 (de) Verfahren zur herstellung von 8-g(a),12-oxido- 13,14,15,16-tetranorlabdan

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties